CoChat

Targeting hypoxic response for cancer therapy

Open access
Paolicchi, Elisa, Gemignani, Federica, Krstic-Demonacos, Marija, Dedhar, Shoukat, Mutti, Luciano, Landi, Stefano · 2016 · Oncotarget
Cited by 88

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

// Elisa Paolicchi 1 , Federica Gemignani 1 , Marija Krstic-Demonacos 2 , Shoukat Dedhar 3 , Luciano Mutti 2,* and Stefano Landi 1,* 1 Genetics-Department of Biology, University of Pisa, Pisa, Italy 2 School of Environment and Life Sciences, College of Science and Technology, University of Salford, Salford, UK 3 Department of Integrative Oncology, BC Cancer Research Centre, BC Cancer Agency and Department of Biochemistry and Molecular Biology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada * Senior authors Correspondence to: Elisa Paolicchi, email: // Keywords : hypoxia, Warburg effect, cancer stem cells, epithelial mesenchymal transition, clinical trials Received : August 04, 2015 Accepted : January 17, 2016 Published : February 07, 2016 Abstract Hypoxic tumor microenvironment (HTM) is considered to promote metabolic changes, oncogene activation and epithelial mesenchymal transition, and resistance to chemo- and radio-therapy, all of which are hallmarks of aggressive tumor behavior. Cancer cells within the HTM acquire phenotypic properties that allow them to overcome the lack of energy and nutrients supply within this niche. These phenotypic properties include activation of genes regulating glycolysis, glucose transport, acidosis regulators, angiogenesis, all of which are orchestrated through the activation of the transcription factor, HIF1A, which is an independent marker of poor prognosis. Moreover, during the adaptation to a HTM cancer cells undergo deep changes in mitochondrial functions such as “Warburg effect” and the “reverse Warburg effect”. This review aims to provide an overview of the characteristics of the HTM, with particular focus on novel therapeutic strategies currently in clinical trials, targeting the adaptive response to hypoxia of cancer cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7229

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 88

Metadata

Authors
Paolicchi, E., Gemignani, F., Krstic-Demonacos, M., Dedhar, S., Mutti, L., & Landi, S.
Venue
Oncotarget
Published
2016-02-07
Volume
7
Issue
12
Pages
13464-13478
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2270969662
Cited by
88
References
15
FWCI
5.94
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting hypoxic response for cancer therapy. https://app.cochat.ai/papers/10.18632/oncotarget.7229
The paper
Paolicchi, E., Gemignani, F., Krstic-Demonacos, M., Dedhar, S., Mutti, L., & Landi, S. (2016). Targeting hypoxic response for cancer therapy. Oncotarget. https://doi.org/10.18632/oncotarget.7229

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.